Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum β-lactamase-producing strain of Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 1, 1999, Pages 91-97

  Mimoz, Olivier ^a   Elhelali, Najoua ^b   Léotard, Sophie ^b   Jacolot, Anne ^c   Laurent, Frederic ^b   Samii, Kamran ^a   Petitjean, Olivier ^c   Nordmann, Patrice ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b BICÊTRE HOSPITAL   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CEFEPIME; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG ELIMINATION; DRUG RESPONSE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RAT; TIME;

AMIKACIN; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; IMIPENEM; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, WISTAR;

EID: 0032816322     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.1.91     Document Type: Article

References (28)

1. Schaberg, D. R., Culver, D. H. & Gaynes, R. P. (1991). Major trends in the microbial etiology of nosocomial infection. American Journal of Medicine 91, Suppl. 3B, 72S-75S.
2. Vincent, J. L., Bihari, D. J., Suter, P. M., Bruining, H. A., White, J., Nicolas-Chanoin, M. H. et al. (1995). The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Journal of the American Medical Association 274, 639-44.
3. Chamberland, S., L'Ecuyer, J., Lessard, C., Bernier, P., Provencher, M. & Bergeron, M. G. (1992). Antibiotic susceptibility profiles of 941 Gram-negative bacteria isolated from septicemic patients thoughout Canada. The Canadian Study Group. Clinical Infectious Diseases 15, 615-28.
4. Mugnier, P., Dubrous, P., Casin, I., Arlel, G. & Collatz, E. (1996). A TEM-derived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 40, 2488-93.
5. Naas, T., Philippon, L. N., Poirel, L., Ronco, E. & Nordmann, P. (1999). An SHV-derived extended spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 43, 1281-4.
6. Philippon, L. N., Naas, T., Bouthors, A. T., Barakett, V. & Nordmann, P. (1997). OXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 41, 2188-95.
7. Nordmann, P., Ronco, E., Naas, T., Duport, C., Michel-Briand, Y. & Labia, R. (1993). Characterization of a novel extended-spectrum β-lactamase from Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 37, 962-9.
8. Vahaboglu, H., Ozturk, R., Aygun, G., Coskunkan, F., Yaman, A., Kaygusuz, A. et al. (1997). Widespread detection of PER-1 type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrobial Agents and Chemotherapy 41, 2265-9.
9. Mimoz, O., Jacolot, A., Padoin, C., Caillon, J., Louchahi, K., Tod, M. et al. (1997). Cefepime and amikacin synergy against a cefotaxime-susceptible strain of Enterobacter cloacae in vitro and in vivo. Journal of Antimicrobial Chemotherapy 39, 363-9.
10. Mimoz, O., Jacolot, A., Padoin, C., Tod, M., Samii, K. & Petitjean, O. (1998). Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae. Journal of Antimicrobial Chemotherapy 41, 367-72.
11. Barbhaiya, R. H., Forgue, S. T., Shyu, W. C., Papp, E. A. & Pittman, K. A. (1987). High pressure liquid chromatographic analysis of BMY 28142 in plasma and urine. Antimicrobial Agents and Chemotherapy 31, 55-9.
12. Fournier, J. L., Ramisse, F., Jacolot, A. C., Szatanik, M., Petitjean, O. J., Alonso, J. M. et al. (1996). Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections. Antimicrobial Agents and Chemotherapy 40, 325-30.
13. Garcia Capdevila, L., López Calull, C., Arroyo, C., Moral, M. A., Mangues, M. A. & Bonal, J. (1997). Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients. Journal of Chromatography B: Biomedical Sciences and Applications 692, 127-32.
14. Fantin, B. & Carbon, C. (1992). In vivo synergism: contribution of animal models. Antimicrobial Agents and Chemotherapy 36, 907-12.
15. Rouby, J. J., Martin De Lasalle, E., Poete, P., Nicholas, M. H., Bodin, L., Jarlier, V. et al. (1992). Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. American Review of Respiratory Disease 146, 1059-66.
16. Craig, W. A., Redington, J. & Ebert, S. C. (1991). Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. Journal of Antimicrobial Chemotherapy 27, Suppl. C, 29-40.
17. Barbhaiya, R. H., Forgue, S. T., Gleason, C. R., Knupp, C. A., Pittman, K. A., Weidler, D. J. et al. (1992) Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrobial Agents and Chemotherapy 36, 552-7.
18. Signs, S. A., Tan, J. S., Salstrom, S. J. & File, T. M. (1992) Pharmacokinetics of imipenem in serum and skin window fluid in healthy adults after intramuscular or intravenous administration. Antimicrobial Agents and Chemotherapy 36, 1400-3.
19. Lanao, J. M., Navarro, A. S., Dominguez-Gil, A., Tabernero, J. M., Rodriguez, I. C. & Gonzalez Lopez, A. (1983) Amikacin concentrations in serum and blister fluid in healthy volunteers and in patients with renal impairment. Journal of Antimicrobial Chemotherapy 12, 481-8
20. Sorgel, F. & Kinzig, M. (1994) Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Medicine 20, Suppl. 3, 14S-20S.
21. Rice, L. B., Carias, L. L. & Shlaes, D. M. (1994). In vivo efficacies of β-lactam-β-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 38, 2663-4.
22. Rice, L. B., Yao, J. D. C., Klimm, K., Eliopoulos, G. M. & Moellering, R. C. (1991). Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrobial Agents and Chemotherapy 35, 1243-4.
23. Thauvin-Eliopoulos, C., Tripodi, M. F., Moellering, R. C. & Eliopoulos, G. M. (1997). Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy 41, 1053-7.
24. Klastersky, J., Meunier-Carpentier, F. & Prevost, J. (1977). Significance of antimicrobial synergism for the outcome of Gram-negative sepsis. American Journal of Medical Sciences 273, 157-67.
25. Dubrous, P., Cavallo, J. D., Hernandez, E., Nordmann P. & Fabre, R. (1997). Pseudomonas aeruginosa: bactéricidie sur différents phénotypes de résistance aux β-lactamines de 8 antibiotiques et 7 associations. Pathologie Biologie 45, 433-7.
26. Mimoz, O., Jacolot, A., Leotard, S., Hidri, N., Samii, K., Nordmann, P. & Petitjean, O. (1998). Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or -resistant Enterobacter cloacae strains. Antimicrobial Agents and Chemotherapy 42, 3304-8.
27. Korvick, J. A. & Yu, V. L. (1991). Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 35, 2167-72.
28. Scott, R. E. & Robson, H. G. (1976). Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats. Antimicrobial Agents and Chemotherapy 10, 646-51.